Adaptam Therapeutics Secures €3m Funding
Adaptam Therapeutics has raised €3m to develop antibody-based cancer immunotherapies targeting myeloid cells.
The pre-seed financing round, led by Criteria Bio Ventures, will enable Adaptam to advance its therapeutic programs into preclinical development.
- First-in-class antibody therapies, including ADCs and bispecific antibodies
- Targeting novel glyco-immune checkpoints in tumour-associated myeloid cells
- Aiming to overcome the immunosuppressive tumour microenvironment (TME)
Adaptam is pioneering therapies to target immunosuppressive myeloid cells.
Dr Salvatore Cappadona and Dr Pablo Cironi from Criteria Bio Ventures have joined Adaptam’s board of directors.
Author's summary: Adaptam Therapeutics raises €3m for cancer therapy development.
More News
- $28 million Glenorchy sports centre inches closer as tender released
- Creepy: GOP Senator Admits Tracking Democratic Colleague's Cars
- A few showers possible to start your weekend
- Mega move incoming? Real Madrid plots Erling Haaland-Kylian Mbappe duo to match Barcelona’s Lamine Yamal brilliance, with little help from Vinicius
- Study Finds Around a Quarter of Polymarket Trades Are Fake
- This 14″ Laptop Monitor Extender Is Nearly Free on Amazon, and It Doubles Your Screen Space
- New WWE ID Signing Announced - WrestleTalk
- Chelsea eyeing free agent deal for Real Madrid star - Get Spanish Football News
- 4-alarm fire in North Baltimore has been contained, SKY 11 reports
- NTSB Briefing Reveals CVR Data in UPS Jet Crash